Paula Pohlmann
Director, Section of Breast Cancer Clinical Research & Professor, Department of Breast Medical Oncology & Department of Investigational Cancer Therapeutics The University of Texas MD Anderson Cancer Center
Dr. Paula Pohlmann specializes in breast cancer and phase I clinical trials. She develops new therapies, including drugs, biologics, and vaccines for patients with solid malignancies, integrating scientific innovation with disciplined trial design and execution. As Director of Breast Cancer Clinical Research at UT MD Anderson Cancer Center, she leads clinical development efforts that span all breast cancer disease stages.
Dr. Pohlmann oversees a broad portfolio of investigator initiated and industry sponsored studies, bringing strategic insight into feasibility assessment, operational planning, and regulatory alignment. Her work focuses on translating emerging platforms, such as immunotherapies, targeted agents, and novel vaccine technologies into rigorous, patient centered clinical trials.
Known for her collaborative approach and ability to bridge scientific concepts with practical clinical strategy, Dr. Pohlmann partners closely with industry teams to refine development pathways and accelerate high quality research across solid tumors. She remains committed to advancing impactful therapies and strengthening networks that drive innovation in oncology and immunology.
Seminars
Establishing clinical trials for personalized cancer vaccines requires aligning regulatory strategy, patient selection, manufacturing logistics, and clinical operations within tight timelines. This workshop will explore practical approaches to trial design, manufacturing integration, immune monitoring, and regulatory planning, sharing key lessons learned to streamline execution and improve clinical development success.
Join this workshop to:
- Navigate regulatory pathways to accelerate approval timelines and reduce compliance risks
- Optimize patient selection strategies to improve enrollment rates and enhance trial outcomes
- Manage costs and resources to maximize budget efficiency and ensure trial sustainability
- Select clinical sites strategically to enhance patient recruitment and data quality
- Learn from trial outcomes to apply proven insights and avoid common pitfalls
- Which patient populations and disease settings offer the greatest opportunity to demonstrate the value of personalized cancer vaccines in clinical development?
- How should developers balance efficacy, durability, toxicity, and operational complexity when designing combination regimens?
- What manufacturing innovations and regulatory strategies are needed to consistently deliver individualized therapies at scale?
